Barclays
KRTX

Barclays’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Barclays’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-82,074
Closed -$26M – 5455
2023
Q4 		$26M Buy
82,074
+8,152
+11% +$1.58M 0.01% 949
2023
Q3 		$12.5M Sell
73,922
-10,394
-12% -$1.95M 0.01% 905
2023
Q2 		$18.3M Buy
84,316
+55,707
+195% +$11.9M 0.01% 756
2023
Q1 		$5.2M Sell
28,609
-836
-3% -$160K ﹤0.01% 1516
2022
Q4 		$5.79M Sell
29,445
-1,653
-5% -$354K ﹤0.01% 1517
2022
Q3 		$6.99M Buy
31,098
+28,682
+1,187% +$5.81M 0.01% 998
2022
Q2 		$306K Sell
2,416
-7,493
-76% -$861K ﹤0.01% 3185
2022
Q1 		$1.26M Sell
9,909
-30,619
-76% -$3.45M ﹤0.01% 2220
2021
Q4 		$5.31M Buy
40,528
+21,575
+114% +$2.79M ﹤0.01% 1668
2021
Q3 		$2.32M Buy
18,953
+1,580
+9% +$182K ﹤0.01% 2216
2021
Q2 		$1.98M Sell
17,373
-12,930
-43% -$1.51M ﹤0.01% 2200
2021
Q1 		$3.64M Sell
30,303
-10,420
-26% -$1.18M ﹤0.01% 1783
2020
Q4 		$4.14M Buy
40,723
+32,476
+394% +$3.01M ﹤0.01% 1647
2020
Q3 		$637K Sell
8,247
-1,048
-11% -$89.3K ﹤0.01% 3047
2020
Q2 		$1.03M Buy
9,295
+5,496
+145% +$478K ﹤0.01% 2727
2020
Q1 		$274K Sell
3,799
-1,338
-26% -$114K ﹤0.01% 4063
2019
Q4 		$387K Buy
5,137
+2,879
+128% +$126K ﹤0.01% 4511
2019
Q3 		$37K Buy
+2,258
New +$43.9K ﹤0.01% 6031

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Barclays's KRTX Position: Q1 2024 in Review

Barclays sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 82,074 shares — an estimated $26M sold.

Barclays first reported a position in KRTX in Q3 2019 and held it in 18 quarters. The position peaked at $26M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Barclays reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Barclays sold 82,074 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $26M.
  • Barclays first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2019 and held it in 18 quarters.
  • Barclays's Karuna Therapeutics, Inc. Common Stock position peaked at $26M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Barclays's 13F filing for Q1 2024, filed 15 May 2024.